Jack Taunton, Ph.D.
Jack Taunton has spent much of his career developing biochemical tools to illuminate cellular processes relevant to cancer and autoimmune diseases. His work designing covalent inhibitors that target protein kinases led to a drug candidate that’s now advancing through clinical trials. He also discovered a family of cyclic depsipeptides that represent a promising new class of oncology drugs. Jack earned his Ph.D. in chemistry from Harvard University and is a co-founder of Global Blood Therapeutics, Principia Biopharma and Kezar Life Sciences.